ContraFect Corporation (CFRX)

NASDAQ: CFRX · IEX Real-Time Price · USD
2.36 -0.08 (-3.28%)
Jan 21, 2022 4:00 PM EST - Market closed
Market Cap92.83M
Revenue (ttm)n/a
Net Income (ttm)-22.29M
Shares Out39.33M
EPS (ttm)-0.66
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume97,434
Open2.40
Previous Close2.44
Day's Range2.28 - 2.51
52-Week Range2.28 - 7.63
Beta0.76
AnalystsStrong Buy
Price Target13.58 (+475.4%)
Earnings Daten/a

About CFRX

ContraFect Corporation, a clinical-stage biotechnology company, focuses on the discovery and development of therapeutic protein and antibody products for the treatment of life-threatening and drug-resistant infectious diseases in the United States. Its lead product candidates consist of CF-301, an investigational novel lysin, which is in Phase III clinical trials for the treatment of staphylococcus aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible. The company also develops CF-296, an engineere...

IndustryBiotechnology
IPO DateJul 29, 2014
CEORoger Pomerantz
Employees33
Stock ExchangeNASDAQ
Ticker SymbolCFRX
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for ContraFect stock is "Strong Buy." The 12-month stock price forecast is 13.58, which is an increase of 475.42% from the latest price.

Price Target
$13.58
(475.42% upside)
Analyst Consensus: Strong Buy

News

ContraFect Announces Award from the Cystic Fibrosis Foundation to Evaluate Exebacase as a Potential Treatment for Ser...

YONKERS, N.Y., Jan. 06, 2022 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

2 weeks ago - GlobeNewsWire

Compassionate Use Case Study Demonstrating the Potential of Investigational Direct Lytic Agent Exebacase to Treat MRS...

Data from Single Pediatric Patient Highlights that FDA-Designated Breakthrough Therapy Exebacase May be a Beneficial Adjunctive Therapy for Severe MRSA Infections in Children Data from Single Pediatric ...

1 month ago - GlobeNewsWire

ContraFect Reports Third Quarter 2021 Financial Results and Provides Corporate Update

YONKERS, N.Y., Nov. 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

2 months ago - GlobeNewsWire

ContraFect's New Data Presented at NACFC Demonstrate Potential of Direct Lytic Agents to Treat Pulmonary Infections i...

Company's Direct Lytic Agents Lysin CF-370 and Amurin Peptide AM1 Show In Vitro Activity Against Prevalent Gram-Negative Pathogens Associated with Lung Infections in Patients with Cystic Fibrosis Compan...

2 months ago - GlobeNewsWire

ContraFect to Present Data on the Potential of DLAs to Treat Pulmonary Infections in Cystic Fibrosis Patients

YONKERS, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

2 months ago - GlobeNewsWire

ContraFect to Present New Late Breaking Phase 2 Exebacase Data on Rapid Symptom Resolution Among Patients with Staphy...

Data Being Presented Demonstrates Directly Positive Clinical Utility and Furthers the Understanding of Exebacase in Treating Staphylococcus aureus Bacteremia, Including Multidrug-Resistant MRSA Data Bei...

3 months ago - GlobeNewsWire

ContraFect Corporation to Present at the 2021 Cantor Global Virtual Healthcare Conference

YONKERS, N.Y., Sept. 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

4 months ago - GlobeNewsWire

ContraFect Reports Second Quarter 2021 Financial Results and Provides Business Update

Multiple peer-reviewed journal publications and presentations at scientific forums drive value and recognition across the Company's DLA portfolio

5 months ago - GlobeNewsWire

ContraFect Announces Multiple Presentations of New Research Data From Its Pipeline of Direct Lytic Agents at the 31st...

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

6 months ago - GlobeNewsWire

ContraFect Announces Multiple Publications on CF-296 Demonstrating Potent In Vivo Antimicrobial Activity

YONKERS, N.Y., July 19, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

6 months ago - GlobeNewsWire

ContraFect Appoints Gary Woodnutt, Ph.D. as Senior Vice President of Translational Sciences and Preclinical Development

YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...

7 months ago - GlobeNewsWire

ContraFect Invited to Present New Research Data From Its Pipeline of Direct Lytic Agents at World Microbe Forum

YONKERS, N.Y., June 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs)...

7 months ago - GlobeNewsWire

ContraFect Announces Multiple Publications on Exebacase, Including First Manuscript on Local Administration of Lysin ...

Exebacase showed the potential to be used in patients with chronic Staphylococci prosthetic knee infection (PKI) to reduce symptoms and improve function

7 months ago - GlobeNewsWire

ContraFect Reports First Quarter 2021 Financial Results and Provides Business Update

Interim futility analysis from the Phase 3 DISRUPT study of exebacase evaluating treatment superiority is anticipated in H2 2021

8 months ago - GlobeNewsWire

ContraFect Announces Issuance of Composition of Matter Patent for CF-370 by the United States Patent and Trademark Of...

YONKERS, N.Y., May 03, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs),...

8 months ago - GlobeNewsWire

ContraFect Invited to Participate in the Cystic Fibrosis Target Product Profile Virtual Symposium

YONKERS, N.Y., April 26, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

8 months ago - GlobeNewsWire

ContraFect Invited to Present at the Inaugural Anti-Infectives Drug Development Summit

YONKERS, N.Y., April 15, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a late clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs...

9 months ago - GlobeNewsWire

ContraFect Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update

Exebacase Phase 3 DISRUPT study enrollment ongoing in patients with Staph aureus bloodstream infections; results from interim futility analysis anticipated in H2 2021

9 months ago - GlobeNewsWire

ContraFect Corporation Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Add...

YONKERS, N.Y., March 22, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatmen...

10 months ago - GlobeNewsWire

ContraFect Corporation Announces Proposed Public Offering of Common Stock

YONKERS, N.Y., March 17, 2021 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on discovering and developing direct lytic agents for the treatmen...

10 months ago - GlobeNewsWire

Why ContraFect, Evoke, Altimmune, Novavax Are Moving Friday

Among the health care stock movers Friday are ContraFect Corporation (NASDAQ: CFRX), Evoke Pharma, Inc. (NASDAQ: EVOK), Altimmune, Inc. (NASDAQ: ALT) and Novavax, Inc. (NASDAQ: NVAX). Here's why the sto...

Other symbols:ALTEVOKNVAX
10 months ago - Benzinga

ContraFect Reports Third Quarter 2020 Financial Results and Provides Business Update

CARB-X and Cystic Fibrosis Foundation grant s provide significant additional funding to advance CF-370 for Pseudomonas aeruginosa infections

1 year ago - GlobeNewsWire

ContraFect Initiates Expanded Access to Exebacase for the Treatment of MRSA Bloodstream Infections in COVID-19 Patients

YONKERS, N.Y., Oct. 26, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX) a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DLAs), incl...

1 year ago - GlobeNewsWire

ContraFect to Present at the 2020 Cantor Global Virtual Healthcare Conference

YONKERS, N.Y., Sept. 09, 2020 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq: CFRX), a clinical-stage biotechnology company focused on the discovery and development of direct lytic agents (DL...

1 year ago - GlobeNewsWire

ContraFect Announces Funding Agreement with the Cystic Fibrosis Foundation

Initial evaluation of Direct Lytic Agents (DLAs) as potential novel modalities to address lung infections caused by antibiotic-resistant Gram-negative bacterial pathogens in Cystic Fibrosis Initial eval...

1 year ago - GlobeNewsWire